 NEW YORK, May 19, 2021 PRNewswire -- Seelos Therapeutics, Inc. Nasdaq: SEEL, a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system CNS disorders and rare diseases, announced today that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. 